A number of pharmacological compounds that stimulate the activity of PPARδ, AMPK and SIRT1 have proven to be efficacious at relieving several DMD symptoms in animal models but there are several hurdles to overcome for their clinical development in DMD patients. The gene discussed is PRKAA2; the disease is Duchenne muscular dystrophy.